-
Article
Open AccessTranscriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mecha...
-
Article
Open AccessImpact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials
Fatigue is a multifactorial symptom commonly reported by patients with prostate cancer as a result of disease and treatment. This study assesses the impact enzalutamide has on patient-reported fatigue (“fatigu...
-
Article
Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?
Due to stay-at-home orders during COVID-19, we transitioned supervised, group, in-person resistance training interventions in two clinical trials in cancer survivors to live, online delivery using video-confer...
-
Article
Open AccessA pilot feasibility study of Exercising Together© during radiation therapy for prostate cancer: a dyadic approach for patients and spouses
Prostate cancer can negatively impact the health of patients and their spouse, particularly early on in the cancer trajectory.
-
Article
Open AccessProtocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer
Many prostate cancer survivors are treated with androgen deprivation therapy (ADT), but these therapies may increase frailty, worsen physical functioning, and increase fall risk. While exercise may counter fun...
-
Article
Open AccessStudy protocol for the Exercising Together© trial: a randomized, controlled trial of partnered exercise for couples co** with cancer
Most cancer survivors are married, and cancer strains the physical and mental health of each partner and their intimate relationship. We created a partnered strength training program, Exercising Together©, whe...
-
Article
The DNA methylation landscape of advanced prostate cancer
Although DNA methylation is a key regulator of gene expression, the comprehensive methylation landscape of metastatic cancer has never been defined. Through whole-genome bisulfite sequencing paired with deep w...
-
Article
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer
Germline variants in androgen metabolism genes may influence clinical response to androgen deprivation therapy (ADT) in advanced prostate cancer. We sought to investigate the prognostic significance of germlin...
-
Article
Open AccessMEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Metastatic castration resistant prostate cancer (mCRPC) is incurable and progression after drugs that target the androgen receptor-signaling axis is inevitable. Thus, there is an urgent need to develop more ef...
-
Article
Combining options in metastatic prostate cancer
Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for indivi...
-
Article
Open AccessA phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
In men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy can be combined with SRT in order to increase prostate tumor control,...
-
Article
Open AccessPublisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both...
-
Article
Open AccessImplementing a comprehensive translational oncology platform: from molecular testing to actionability
In order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and ana...
-
Article
Open AccessInterplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
Despite recent advances, the efficacy of androgen/androgen receptor (AR)-targeted therapy remains limited for many patients with metastatic prostate cancer. This is in part because prostate cancers adaptively...
-
Article
Open AccessHealth-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial
The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D ins...
-
Article
Open AccessThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have be...
-
Article
Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project
Prostate cancer can negatively impact quality of life of the patient and his spouse caregiver, but interventions rarely target the health of both partners simultaneously. We tested the feasibility and prelimin...
-
Article
The new and the old that is new again
In 2015, published trials highlighted the remarkable efficacy of docetaxel combined with androgen-deprivation therapy in patients with newly diagnosed metastatic prostate cancer. Also in 2015, a large study re...
-
Article
Open AccessAutologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
-
Article
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer
Diets high in cruciferous vegetables are associated with lower risk of incidence of prostate cancer, including aggressive forms of this disease. Human intervention studies with cruciferous vegetable-rich diets...
